Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA

BACKGROUND: We assessed the efficacy of the licensed mepolizumab dose (100 mg subcutaneously [SC]) in patients with severe eosinophilic asthma according to body weight/body mass index (BMI). METHODS: This was a post hoc individual patient-level meta-analysis of data from the Phase 3 studies MENSA (M...

Descripción completa

Detalles Bibliográficos
Autores principales: Albers, Frank C., Papi, Alberto, Taillé, Camille, Bratton, Daniel J., Bradford, Eric S., Yancey, Steven W., Kwon, Namhee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6664536/
https://www.ncbi.nlm.nih.gov/pubmed/31362741
http://dx.doi.org/10.1186/s12931-019-1134-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6664536/
https://www.ncbi.nlm.nih.gov/pubmed/31362741
http://dx.doi.org/10.1186/s12931-019-1134-7

Ejemplares similares